CCA
AXDX

Catalyst Capital Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Catalyst Capital Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,000
Closed -$258K – 538
2015
Q2 		$258K Buy
+1,000
New +$239K 0.03% 290

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
MGM
Miura Global Management New York $43.8M AUM 53.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

Catalyst Capital Advisors's AXDX Position: Q3 2015 in Review

Catalyst Capital Advisors sold out of Accelerate Diagnostics (AXDX) in Q3 2015, closing a stake of 1,000 shares — an estimated $258K sold.

Catalyst Capital Advisors first reported a position in AXDX in Q2 2015 and held it in 1 quarter. The position peaked at $258K in Q2 2015. 88 funds tracked by Wall St. Rank hold AXDX as of Q3 2015.

  • Catalyst Capital Advisors reported no remaining Accelerate Diagnostics position as of Q3 2015 after selling out during the quarter.
  • Catalyst Capital Advisors sold 1,000 Accelerate Diagnostics shares in Q3 2015, an estimated $258K.
  • Catalyst Capital Advisors first reported a position in Accelerate Diagnostics in Q2 2015 and held it in 1 quarter.
  • Catalyst Capital Advisors's Accelerate Diagnostics position peaked at $258K in Q2 2015.
  • 88 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2015.

Based on Catalyst Capital Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.